Pharmaceutical Crystals: Materials Engineering and Manufacturing

A special issue of Crystals (ISSN 2073-4352). This special issue belongs to the section "Organic Crystalline Materials".

Deadline for manuscript submissions: closed (28 December 2021) | Viewed by 3926

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA
Interests: formulation; solid-state chemistry; powder technology; crystal engineering; materials science and engineering; drug solubilization; mechanical properties
Special Issues, Collections and Topics in MDPI journals
Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA, USA
Interests: process crystallization; advanced manufacturing and materials engineering; multiphase flow; process design and control; reaction engineering; separations

E-Mail
Guest Editor
Biogen, Inc., Cambridge, MA, USA
Interests: formulation; crystallization; crystal engineering; structure determination; crystal structure prediction; continuous processing

Special Issue Information

Dear Colleagues,

Crystals, an open access journal, is publishing a Special Issue entitled “Pharmaceutical Crystals: Materials Engineering and Manufacturing” and has approached us to guest edit this themed issue. In this regard, we would be very pleased if you would agree to contribute either an original research paper, short communication, or review to this issue. Provided below is some information that you may find useful in your consideration of this invitation.

Crystals play an indispensable role in various steps of active pharmaceutical ingredient (API) manufacturing. Isolation and characterization of new crystalline phases of an API remain critical to the drug development process. Recent years have witnessed rapidly increased research into solution crystallization for reproducible and inexpensive manufacturing of high-quality drug products. Achieving target solid forms and/or crystal properties (e.g., chemical purity, polymorph, phase purity, crystal size distribution, and morphology) with desired process outcomes (e.g., yield, production rate) through crystallization is a typical goal of drug development. This Special Issue welcomes all works pertaining to pharmaceutical crystals, including both experimental and computational studies. Works ranging from thorough solid-state characterization of new APIs to fundamental understanding of the crystallization process fall within the scope of this Special Issue. Both small molecules and proteins are of interest. The intention is to capture a snapshot of the current role that crystals play during drug development.

We would appreciate hearing from you within two weeks as to whether you would like to submit a paper, so that we can make the necessary arrangements. We sincerely hope this invitation will receive your favorable consideration.

Many thanks and warm personal regards.

Prof. Dr. Changquan Sun
Dr. Mo Jiang
Dr. Matthew L. Peterson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Crystals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Novel crystallization process
  • Crystal engineering
  • Polymorphs, salts, cocrystals, hydrates, and solvates
  • Solid-state characterization
  • Size distribution and shape
  • Computation
  • Continuous crystallization
  • Crystal structure prediction

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 6312 KiB  
Article
Discovery, Characterization, and Pharmaceutical Applications of Two Loratadine–Oxalic Acid Cocrystals
by Zhengxuan Liang, Hongbo Chen, Chenguang Wang and Changquan Calvin Sun
Crystals 2020, 10(11), 996; https://0-doi-org.brum.beds.ac.uk/10.3390/cryst10110996 - 03 Nov 2020
Cited by 3 | Viewed by 3460
Abstract
Loratadine (Lor) is an antihistamine drug commonly used to relieve the symptoms of allergy. It has high permeability but low solubility under physiological conditions. To overcome the problem of low solubility, we synthesized and characterized two Loratadine multi-component crystalline phases with oxalic acid [...] Read more.
Loratadine (Lor) is an antihistamine drug commonly used to relieve the symptoms of allergy. It has high permeability but low solubility under physiological conditions. To overcome the problem of low solubility, we synthesized and characterized two Loratadine multi-component crystalline phases with oxalic acid (Oxa), i.e., a 1:1 Lor-Oxa conjugate acid-base (CAB) cocrystal (Lor-Oxa CAB) and a 2:1 Lor-Oxa cocrystal monohydrate (Lor-Oxa hydrate). Both cocrystals exhibited an enhanced solubility and intrinsic dissolution rate (IDR) compared to Lor and adequate physical stability. The intrinsic dissolution rate of Lor-Oxa CAB is 95 times that of Lor, which makes it a promising candidate for tablet formulation development. Full article
(This article belongs to the Special Issue Pharmaceutical Crystals: Materials Engineering and Manufacturing)
Show Figures

Graphical abstract

Back to TopTop